Here's Why Royalty Pharma (NASDAQ:RPRX) Has A Meaningful Debt Burden
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.
Cytokinetics Slips 18% After It Announces Funding Collaboration With Royalty Pharma
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
Cytokinetics (CYTK) disclosed a collaboration late Wednesday under which Royalty Pharma (RPRX) will provide capital totaling up to $575 million to support the commercialization of aficamten and advanc
Cytokinetics Falls 10% on Royalty Pharma Transaction, Stock Offer
By Josh Beckerman Cytokinetics shares were down 10%, to $53.25, after hours as the biopharmaceutical company announced an expanded funding collaboration with Royalty Pharma totaling up to $575 millio
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company's expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.
Express News | Cytokinetics Inc - Cytokinetics Will Receive $100 Mln in Upfront Capital to Fund a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil
Express News | Cytokinetics Inc - Royalty Pharma Will Now Receive 4.5% up to $5.0 Bln of Annual Net Sales of Aficamten and 1% Above $5.0 Bln of Annual Net Sales
Express News | Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
The Leukemia & Lymphoma Society Is Accepting Applications for Up to $2.5 Million in Funding Through Its Equity in Access Research Program
RYE BROOK, N.Y., May 22, 2024 /PRNewswire/ -- Today, The Leukemia & Lymphoma Society's (LLS) Equity in Access Research Program announced the opening of its application process for the 2025 funding cy
S&P 500 Futures Steady In Premarket Trading; RBC Bearings, GameStop Lag
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Reddit Inc. (RDDT) was up 11.2% in pre-market tradi
Royalty Pharma To Go Ex-Dividend On May 16th, 2024 With 0.21 USD Dividend Per Share
May 15th - $Royalty Pharma(RPRX.US)$ is trading ex-dividend on May 16th, 2024. Shareholders of record on May 17th, 2024 will receive 0.21 USD dividend per share on June 14th, 2024. The ex-dividend
Express News | Royalty Pharma PLC : Morgan Stanley Raises Target Price to $48.00 From $46.00
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024
Here's What Analysts Are Forecasting For Royalty Pharma Plc (NASDAQ:RPRX) After Its First-Quarter Results
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Q1 2024 Royalty Pharma PLC Earnings Call
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading
Health care stocks were rising Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.8%. The iShares Biotechnology ETF (IBB) rose 0.7%. In